A study has found that the total cost of medical practice interaction with insurers is $21-$31 billion a year, or more than $68,000 per physician on average, according to an MGMA news release.
Uncategorized
While ASCs face a variety of legal issues at their individual state levels, there are several national legal issues affecting the everyday affairs of a surgery center, according to ASC legal experts. The most critical are physician ownership, safe harbor…
McGuireWoods is pleased to announce that Chicago office partner Ed Brooks was recently appointed vice chair of Healthcare Liability and Litigation Practice Group of the American Health Lawyers Association.
This is a short summary of 15 anti-kickback and fraud cases and investigations that have made headlines in 2009. The situations involve a range of participants including hospitals, device companies, physicians, payors and other suppliers.
Amkai, a software company with 20-plus years of experience delivering administrative and clinical solutions to ASCs, surgical hospitals and physician practices, is hosting a free webinar titled "How Comprehensive Information Management Boosts ASC Performance" on Tue., June 23 from 1-2…
Advertisement
Woodrum/ASD, an ambulatory surgery development and management company, has an immediate opening for an assistant director of business office operations.
Madhavi Rampalli, CPA, is seeking a senior executive position in healthcare finance. Ms. Rampalli has worked in healthcare for the past 11 years and currently serves as the CFO of Chicago-based Magna Health Systems. One of her strengths is her…
Officials from the Obama administration announced that due to the recession, the Medicare fund is expected to run out of money by 2017, two years earlier than had been previously predicted, according to a report in The New York Times.
The Shands Children's Surgical Center in Gainesville, Fla., recently reopened after renovation thanks to a $238,000 grant from the Children's Miracle Network, according to a report by The Gainesville Sun.
The U.S. Food and Drug Administration will review its decision to approve the Menaflex knee-surgery device after several scientists and FDA managers raised objections over the approval process, according to an article in The Wall Street Journal.